A new Centiloid method for 18F-florbetaben and 18F-flutemetamol PET without conversion to PiB (original) (raw)

Abstract

Purpose

We developed a new method to directly calculate Centiloid (CL) units of 18F-florbetaben (FBB) and 18F-flutemetamol (FMM) without conversion to the PiB standardized uptake value ratio (SUVR).

Methods

Paired FBB and FMM PET scans were obtained from 20 Alzheimer’s disease–related cognitive impairment patients, 16 old controls, and 20 young controls. We investigated the correlations between the FBB and FMM CL units using the direct comparison of FBB-FMM CL (dcCL) method and the standard CL method and compare differences in FBB and FMM CL units between dcCL method and the standard method.

Results

Following the conversion of FBB or FMM SUVRs into CL units, a direct relationship was formed between the FBB or FMM SUVRs and the CL units using dcCL method (FBB dcCL = 151.42 × FBB dcSUVR − 142.24 and FMM dcCL = 148.52 × FMM dcSUVR − 137.09). The FBB and FMM CL units were highly correlated in both our method (_R_2 = 0.97, FMM dcCL = 0.97 × FBB dcCL + 1.64) and the standard method (_R_2 = 0.97, FMM CLstandard = 0.79 × FBB CLstandard + 1.36). However, the CL variations between FBB and FMM were smaller when calculated by dcCL method (6.15) than when calculated by the previous method (10.22; P = 0.01).

Conclusions

Our findings suggest that our direct comparison of FBB-FMM method, rather than the standard method, is a reasonable way to convert FBB or FMM SUVRs into CL units, at least in environments where FBB or FMM ligands are used frequently.

Access this article

Log in via an institution

Subscribe and save

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Change history

Funding information from the original version of this article was incomplete. Complete information is presented here.

References

  1. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306–19.
    Article CAS Google Scholar
  2. Wong DF, Rosenberg PB, Zhou Y, Kumar A, Raymont V, Ravert HT, et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med. 2010;51:913–20.
    Article CAS Google Scholar
  3. Barthel H, Gertz HJ, Dresel S, Peters O, Bartenstein P, Buerger K, et al. Cerebral amyloid-beta PET with florbetaben (18F) in patients with Alzheimer’s disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011;10:424–35.
    Article CAS Google Scholar
  4. Rinne JO, Wong DF, Wolk DA, Leinonen V, Arnold SE, Buckley C, et al. [(18)F] Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid beta detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies. Acta Neuropathol. 2012;124:833–45.
    Article CAS Google Scholar
  5. Landau SM, Thomas BA, Thurfjell L, Schmidt M, Margolin R, Mintun M, et al. Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging. 2014;41:1398–407.
    Article CAS Google Scholar
  6. Rowe CC, Dore V, Jones G, Baxendale D, Mulligan RS, Bullich S, et al. (18)F-Florbetaben PET beta-amyloid binding expressed in Centiloids. Eur J Nucl Med Mol Imaging. 2017;44:2053–9.
    Article CAS Google Scholar
  7. Battle MR, Pillay LC, Lowe VJ, Knopman D, Kemp B, Rowe CC, et al. Centiloid scaling for quantification of brain amyloid with [(18)F] flutemetamol using multiple processing methods. EJNMMI Res. 2018;8:107.
    Article Google Scholar
  8. Carbonell F, Zijdenbos AP, Charil A, Grand’Maison M, Bedell BJ. Optimal target region for subject classification on the basis of amyloid PET images. J Nucl Med. 2015;56:1351–8.
    Article CAS Google Scholar
  9. Landau SM, Fero A, Baker SL, Koeppe R, Mintun M, Chen K, et al. Measurement of longitudinal beta-amyloid change with 18F-florbetapir PET and standardized uptake value ratios. J Nucl Med. 2015;56:567–74.
    Article CAS Google Scholar
  10. Tudorascu DL, Minhas DS, Lao PJ, Betthauser TJ, Yu Z, Laymon CM, et al. The use of Centiloids for applying [(11)C] PiB classification cutoffs across region-of-interest delineation methods. Alzheimers Dement (Amst). 2018;10:332–9.
    Google Scholar
  11. Klunk WE, Koeppe RA, Price JC, Benzinger TL, Devous MD Sr, Jagust WJ, et al. The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement. 2015;11:1-15.e1-4.
    Article Google Scholar
  12. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol. 2013;12:357–67.
    Article CAS Google Scholar
  13. Navitsky M, Joshi AD, Kennedy I, Klunk WE, Rowe CC, Wong DF, et al. Standardization of amyloid quantitation with florbetapir standardized uptake value ratios to the Centiloid scale. Alzheimers Dement. 2018;14:1565–71.
    Article Google Scholar
  14. Park JH, Seo SW, Kim C, Kim GH, Noh HJ, Kim ST, et al. Pathogenesis of cerebral microbleeds: in vivo imaging of amyloid and subcortical ischemic small vessel disease in 226 individuals with cognitive impairment. Ann Neurol. 2013;73:584–93.
    Article CAS Google Scholar
  15. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9.
    Article Google Scholar
  16. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56:303–8.
    Article CAS Google Scholar
  17. Kim HJ, Yang JJ, Kwon H, Kim C, Lee JM, Chun P, et al. Relative impact of amyloid-beta, lacunes, and downstream imaging markers on cognitive trajectories. Brain. 2016;139:2516–27.
    Article Google Scholar
  18. Jang H, Jang YK, Kim HJ, Werring DJ, Lee JS, Choe YS, et al. Clinical significance of amyloid beta positivity in patients with probable cerebral amyloid angiopathy markers. Eur J Nucl Med Mol Imaging. 2019;46:1287–98.
    Article CAS Google Scholar
  19. Kim SE, Woo S, Kim SW, Chin J, Kim HJ, Lee BI, et al. A nomogram for predicting amyloid PET positivity in amnestic mild cognitive impairment. J Alzheimers Dis. 2018;66:681–91.
    Article CAS Google Scholar
  20. Barthel H, Bullich S, Sabri O, Seibyl J, Villemagne V, Rowe C, et al. 18F-Florbetaben (FBB) PET SUVR quantification: which reference region? J Nucl Med. 2015;56:1563.
    Google Scholar
  21. Farrar G. Regional visual read inspection of [18F]flutemetamol brain images from end-of-life and amnestic MCI subjects. J Nucl Med. 2017;58:1250.
    Google Scholar
  22. Sled JG, Zijdenbos AP, Evans AC. A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging. 1998;17:87–97.
    Article CAS Google Scholar
  23. Yun HJ, Moon SH, Kim HJ, Lockhart SN, Choe YS, Lee KH, et al. Centiloid method evaluation for amyloid PET of subcortical vascular dementia. Sci Rep. 2017;7:16322.
    Article Google Scholar
  24. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1:307–10.
    Article CAS Google Scholar
  25. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1:a006189.
    Article Google Scholar
  26. Villemagne VL, Mulligan RS, Pejoska S, Ong K, Jones G, O’Keefe G, et al. Comparison of 11C-PiB and 18F-florbetaben for Abeta imaging in ageing and Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2012;39:983–9.
    Article CAS Google Scholar
  27. Mountz JM, Laymon CM, Cohen AD, Zhang Z, Price JC, Boudhar S, et al. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer’s subjects. Neuroimage Clin. 2015;9:592–8.
    Article Google Scholar
  28. Lowe VJ, Lundt E, Knopman D, Senjem ML, Gunter JL, Schwarz CG, et al. Comparison of [(18)F]Flutemetamol and [(11)C]Pittsburgh Compound-B in cognitively normal young, cognitively normal elderly, and Alzheimer’s disease dementia individuals. Neuroimage Clin. 2017;16:295–302.
    Article Google Scholar
  29. Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol. 2010;68:319–29.
    Article Google Scholar

Download references

Funding

This research was supported by a National Research Foundation of Korea grant funded by the Korean government (MSIP) (No. NRF-2017R1A2B2005081) and by Research of Korea Centers for Disease Control and Prevention (No. 2018-ER6203-01).

Author information

Author notes

  1. Soo Hyun Cho and Yeong Sim Choe contributed equally to this article as co-first authors.
    Seongbeom Park and Sang Won Seo contributed equally to this article as co-corresponding authors.

Authors and Affiliations

  1. Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    Soo Hyun Cho, Yeong Sim Choe, Hee Jin Kim, Hyemin Jang, Yeshin Kim, Si Eun Kim, Seung Joo Kim, Jun Pyo Kim, Young Hee Jung, Duk L. Na, Seongbeom Park & Sang Won Seo
  2. Department of Neurology, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Korea
    Soo Hyun Cho & Byeong C. Kim
  3. Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea
    Yeong Sim Choe, Duk L. Na & Sang Won Seo
  4. Neuroscience Center, Samsung Medical Center, Seoul, Korea
    Yeong Sim Choe, Hee Jin Kim, Hyemin Jang, Jun Pyo Kim, Duk L. Na, Seongbeom Park & Sang Won Seo
  5. Department of Neurology, Kangwon National University Hospital, Kangwon National University College of Medicine, Chuncheon, Korea
    Yeshin Kim
  6. Department of Neurology, Inje University College of Medicine, Haeundae Paik Hospital, Busan, Korea
    Si Eun Kim
  7. Department of Neurology, Gyeongsang National University School of Medicine and Gyeongsang National University Changwon Hospital, Changwon, Korea
    Seung Joo Kim
  8. Department of Neurology, Myoungji Hospital, Hanyang University, Goyangsi, Korea
    Young Hee Jung
  9. Molecular Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, CA, USA
    Suzanne L. Baker
  10. Internal Medicine - Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA
    Samuel N. Lockhart
  11. Stem Cell & Regenerative Medicine Institute, Samsung Medical Center, Seoul, Korea
    Duk L. Na
  12. Department of Clinical Research Design & Evaluation, SAIHST, Sungkyunkwan University, Seoul, Korea
    Sang Won Seo
  13. Samsung Alzheimer Research Center, Samsung Medical Center,, Seoul, Korea
    Sang Won Seo
  14. Center for Clinical Epidemiology, Samsung Medical Center, Seoul, Korea
    Sang Won Seo

Authors

  1. Soo Hyun Cho
  2. Yeong Sim Choe
  3. Hee Jin Kim
  4. Hyemin Jang
  5. Yeshin Kim
  6. Si Eun Kim
  7. Seung Joo Kim
  8. Jun Pyo Kim
  9. Young Hee Jung
  10. Byeong C. Kim
  11. Suzanne L. Baker
  12. Samuel N. Lockhart
  13. Duk L. Na
  14. Seongbeom Park
  15. Sang Won Seo

Contributions

S.H.C., Y.S.C., and S.W.S. contributed to the conceptualization of the study, analysis and interpretation of data, and drafting. Y.S.C. and S.B.P. contributed to analyses of imaging data, prepared the figures, and provided technical support. B.C.K., H.J.K., H.M.J., Y.S.K., S.E.K., S.J.K., J.P.K., Y.H.J., and D.L.N. contributed to the interpretation of data. S.L.B. and S.N.L. drafted the manuscript.

Corresponding authors

Correspondence toSeongbeom Park or Sang Won Seo.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Disclaimer

The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Neurology

Electronic supplementary material

Rights and permissions

About this article

Cite this article

Cho, S., Choe, Y.S., Kim, H.J. et al. A new Centiloid method for 18F-florbetaben and 18F-flutemetamol PET without conversion to PiB.Eur J Nucl Med Mol Imaging 47, 1938–1948 (2020). https://doi.org/10.1007/s00259-019-04596-x

Download citation

Keywords